BiQ: The Ziftomenib-Revumenib Debate 12/10/25 (KURA, SNDX)

While it's still early innings and there is much more data to come, I've noticed there seems to be a fair amount of confusion around recent data for Ziftomenib and Revumenib, so I thought this would be a good time to share my perspective on the most recent data for both drugs in the 1L chemo-ineligible setting. This chart was previously shared with BiQ members in the chat forum.

Please refer to the BiQAP Live spreadsheet on the Active Portfolio page or the iQCS for additional information.

KURA share price at time of publication: $10.74
BiQ Adjusted Cost Basis: $5.73

Not a BiQ Premium member, or have a friend who may be interested? Try BiQ Premium for $50 per month, or $250 (50% off) for the first year.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.